| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FCA.09.31 |
| P698 | PubMed publication ID | 19715410 |
| P2093 | author name string | C Venkata S Ram | |
| P2860 | cites work | The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 |
| Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril | Q28215905 | ||
| Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients | Q28236175 | ||
| Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis | Q28280366 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition | Q29615691 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| Effect of the new diagnostic criteria for ST-elevation and non-ST-elevation acute myocardial infarction on 4-year hospitalization: an analysis of hospital discharge records in the Veneto Region | Q33241456 | ||
| Angiotensin II receptor antagonists | Q33851581 | ||
| Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril | Q34059547 | ||
| A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure | Q34106793 | ||
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial | Q34246891 | ||
| Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial | Q34327991 | ||
| Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q34522261 | ||
| Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers | Q36592289 | ||
| Clinical pharmacokinetics and pharmacodynamics of aliskiren | Q37210472 | ||
| The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point | Q37386077 | ||
| Managing cardiovascular and renal risk: the potential of direct renin inhibition | Q37510348 | ||
| Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both | Q39669015 | ||
| Aliskiren accumulates in Renin secretory granules and binds plasma prorenin | Q39921808 | ||
| Direct Renin inhibition with aliskiren in obese patients with arterial hypertension | Q42165771 | ||
| Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure | Q43266277 | ||
| Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). | Q44205751 | ||
| Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren | Q44642058 | ||
| Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program | Q46083552 | ||
| Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy | Q46157336 | ||
| Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide | Q46165937 | ||
| Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study | Q46208322 | ||
| Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients | Q46217490 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
| Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial | Q46732967 | ||
| Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension | Q46801334 | ||
| Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension | Q46866932 | ||
| Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy | Q46965417 | ||
| Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators | Q48118604 | ||
| Essential hypertension: renin and aldosterone, heart attack and stroke. | Q54460542 | ||
| Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. | Q55042793 | ||
| Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. | Q55042824 | ||
| 2007 Guidelines for the Management of Arterial Hypertension | Q56970780 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 453-465 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Future Cardiology | Q15765184 |
| P1476 | title | Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease | |
| P478 | volume | 5 |
| Q46677439 | Circulating and local renin-angiotensin-aldosterone system express differently in atrial fibrillation patients with different types of mitral valvular disease | cites work | P2860 |
Search more.